Results 131 to 140 of about 27,995 (239)

Psychometric Properties of the Choosing Wisely Questions in a Large Psychiatric Sample

open access: yesInternational Journal of Methods in Psychiatric Research, Volume 35, Issue 4, December 2026.
ABSTRACT Objectives The Choosing Wisely Questions (CWQ) support shared decision‐making and aim to reduce low‐value care, but their psychometric properties remain unclear. This study evaluated the structural validity, reliability, and item characteristics of the Swedish CWQ in a psychiatric sample.
Johan Bengtsson   +6 more
wiley   +1 more source

Comparison of oral absorption models for pregabalin: usefulness of transit compartment model

open access: yes, 2016
Taegon Hong,1 Seunghoon Han,2,3 Jongtae Lee,2,3 Sangil Jeon,4 Dong-Seok Yim2,3 1Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, 2Department of Clinical Pharmacology and Therapeutics, Seoul St Mary’s ...
Jeon S, Hong T, Lee J, Yim DS, Han S
core  

Efficacy of pregabalin in childhood refractory partial seizure [PDF]

open access: yes, 2014
Objective\ud \ud - About one third of partial seizures are refractory to treatment. Several anticonvulsant drugs have entered the market in recent decades but concerns about intolerance, drug interactions, and the safety of the drug are notable.
Rezaei, Nima   +4 more
core  

Patient Experiences of Chronic Low Back Pain: Development of a Conceptual Model Based on a Targeted Literature Review and Qualitative Patient Interviews

open access: yesMusculoskeletal Care, Volume 24, Issue 4, December 2026.
ABSTRACT Purpose Chronic low back pain (CLBP) is a persistent, debilitating condition. The United States (US) Food and Drug Administration Patient‐Focused Drug Development Guidance recommends using patient‐reported outcome (PRO) measures to assess pain and function in clinical trials and document content validity of the measures based on patient ...
Ekin Seçinti   +12 more
wiley   +1 more source

Pregabalin dependence: A case report

open access: yes, 2015
Pregabalin is a new generation antiepileptic that exerts its effect by decreasing the release of such neurotransmitters as glutamate, noradrenaline, and substance P.
Altintoprak A.E.   +2 more
core  

Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA‐76 as a Novel Analgesic in Male Rats and Mice

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT Clinically used analgesics such as gabapentinoids and opioids have limited efficacy and adverse effects like abuse liability, and there is a dire need for novel analgesics with improved safety profiles. Since lysophosphatidic acid can induce neuropathic pain in rodents, LPA receptor antagonists have been investigated as potential analgesics ...
Kristen L. Woodhouse   +6 more
wiley   +1 more source

Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

open access: yes, 2015
Miguel A Ruiz,1 Enrique Álvarez,2 Jose L Carrasco,3 José M Olivares,4 María Pérez,5 Javier Rejas6 1Department of Methodology, School of Psychology, Universidad Autónoma de Madrid, Madrid, 2Department of Psychiatry ...
Álvarez E   +5 more
core  

Community Pharmacists' Perspectives and Experiences of Deprescribing in Québec, Canada: Findings From a Survey

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 6, December 2026.
ABSTRACT Background Community pharmacists in Quebec can bill for deprescribing. However, uptake remains low. We aimed to explore how community pharmacists perceive and engage in deprescribing. Methods Community pharmacists were invited to complete an online survey through a pharmacists' social media group and a newsletter.
Alexandre Campeau Calfat   +2 more
wiley   +1 more source

Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11946-11954, December 2026.
ABSTRACT Aims Crisugabalin (HSK16149), a selective γ‐aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown. Materials and Methods This multicentre randomized controlled trial was conducted
Yaming Li   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy